Copper radionuclides and radiopharmaceuticals in nuclear medicine

Nuclear Medicine and Biology

Volumn 23, Issue 8, 1996, Pages 957-980

  Blower, Philip J ^a,b   Lewis, Jason S ^b   Zweit, Jamal ^c  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

copper; imaging; PET; PTSM; radiopharmaceuticals; targeted radiotherapy

Indexed keywords

BLEOMYCIN; CARBOXYLIC ACID DERIVATIVE; CHELATING AGENT; COPPER 60; COPPER 61; COPPER 62; COPPER 64; COPPER 66; COPPER 67; DITHIOCARBAMIC ACID; FATTY ACID DERIVATIVE; MONOCLONAL ANTIBODY; PENICILLAMINE; POLYAMINE; PORPHYRIN DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

CONTROLLED STUDY; DRUG SYNTHESIS; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE THERAPY; REVIEW;

EID: 0030292909     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(96)00130-8     Document Type: Article

References (210)

1. 1. Abrams M. J., Bradley F. and Giadomenico C. M. (1991) Copper radiosensitizers. European Patent, 0 411 935 A3.
2. 64Cu on Ehrlich ascites tumour cells. Annu. Rep. Res. Reactor Inst. Kyoto Univ. 11, 72-78.
3. 3. Anderson C. J., Connett J. M., Schwarz S. W., Rocque P. A., Guo L. W., Philpott G. W., Zinn K. R., Meares C. F. and Welch M. J. (1992) Copper-64-labeled antibodies for PET imaging. J. Nucl. Med. 33, 1685-1691.
4. 2) for improved biodistribution. J. Nucl. Med. 34, 28P.
5. 5. Anderson C. J., Rocque P. A., Weinheimer C. J. and Welch M. J. (1993) Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging. Nucl. Med. Biol. 20, 461-4 67.
6. 6. Anderson C. J., Connett J. M., Guo L. W., Schwarz S. W., Philpott G. W., Zinn K. R. and Welch M. J. (1994) Initial comparison of Cu-67 and Cu-64-labeled anti-colorectal carcinoma Mab 1A3 as agents for radioimmunotherapy in tumor-bearing hamsters. J. Nucl. Med. 35, 161P.
7. 7. Anderson C. J., Edwards W. B., Pajeau T. S., Zinn K. R. and Welch M. J. (1994) Cu-64-TETA-D-Phe-1-Octreotide: A positron emitting somatostatin receptor imaging agent with receptor binding and renal clearance similar to In-111-DTPA-D-Phe-1-Octreotide. J. Nucl. Med. 35, 106P.
8. 8. Anderson C. J., Sherman E. L. C., Lanahan M. V., Pajeau T. S., Edwards W. B. and Welch M. J. (1995) Biodistribution in a tumor-bearing animal model and metabolism of two Cu-64-labeled octreotide analogs. J. Nucl. Med. 36, 114P.
9. 2. J. Nucl. Med. 36, 850-858.
10. 10. Anderson C. J., Pajeau T. S., Edwards W. B., Sherman E. L. C., Rogers B. E. and Welch M. J. (1995) In vitro and in vivo evaluation of copper-64-octreotide conjugates. J. Nucl. Med. 36, 2315-2325.
11. 11. Anderson C. J., Connett J. M., Schwarz S. W., Guo L. W., Baumann M. L., Zinn K. R. and Welch M. J. (1995) Comparison of radioimmunotherapy (RIT) in colorectal tumor-bearing hamsters with Cu-64 and Cu-67-labeled Mab 1A3.J. Nucl. Med. 36, 217P.
12. 12. Antholine W. E., Gunn P. and Hopwood L. E. (1981) Combined modality of 2-formylpyridine monothiosemicarbazonato copper (II) and radiation. Int. J. Radiat. Oncol. Biol. Phys. 7, 491-495.
13. 13. Antholine W. E., Basosi R., Hyde J. S., Lyman S. and Petering D. H. (1984) Immobile-and mobile-phase ESR spectroscopy of copper complexes: Studies on biologically interesting bis(thiosemicarbazonato) copper(II) chelates. Inorg. Chem. 23, 3543-3548.
14. 2. Koord. Khim. 18, 474-480.
15. 15. Apelgot S., Coppey J., Grisvard J., Guille E. and Sissoeff I. (1981) Distribution of copper-64 in control mice and in mice bearing ascites Krebs tumor cells. Cancer Res. 41, 1502-1507.
16. 64Cu atoms incorporated in cells under either in vitro or in vivo conditions. Radiat. Environ. Biophys. 26, 115-123.
17. 67Cu. Int. J. Radiat. Biol. 55, 365-384.
18. 64Cu labeling of fatty acid analogs containing dithiosemicarbazone chelate. Appl. Radiat. Isot. 40, 745-749.
19. 19. Babich J. W., Cherry S. R., Camochan P., McGuire J. and Sharma H. (1989) An evaluation of Cu-64 pyruveldehyde bis(methylthiosemicarbazone) (PTSM) for the measurement of tissue perfusion. J. Nucl. Med. 30, 1756P.
20. 20. Badertscher R. R. (1984) Copper-64 as a radiopharmaceutical for canine prostate imaging. PhD Thesis, Texas A&M University. PB91808.
21. 67Cu-labeled Cu-PTSM. Nucl. Med. Biol. 19, 697-701.
22. 22. Baker R. J., McLaren A. B., Bellen J. C. and Penglis S. (1987) The effect of lipophilic substutuents on the biological properties of EDTA complexes containing paramagnetic metal ions. Nucl. Med. Biol. 14, 123-126.
23. 23. Barnhart A. J. and Green M. A. (1990) Examination of the effects of glutathione depletion on Cu(PTSM) biodistribution. J. Nucl. Med. 31, 910P.
24. 24. Beanlands R., Muzik O., Lee K., Mintum M., Mangner T., Moskwa J., Hutchins G., Allman K., Petry N., Nguyen N. and Schwaiger M. (1991) Evaluation of Copper-62 PTSM as a myocardial flow tracer. J. Nucl. Med. 32, 1028P.
25. 25. Beanlands R. S. B., Muzik O., Mintun M., Mangner T., Lee K., Petry N., Hutchins G. D. and Schwaiger M. (1992) The kinetics of copper-62-PTSM in the normal human heart. J. Nucl. Med. 33, 684-690.
26. 26. Bernardo M. M., Robandt P. V., Schroeder R. R. and Rorabacher D. B. (1989) Evidence for a square scheme involving conformational intermediates in electron-transfer reactions of copper(II) systems. J. Am. Chem. Soc. 111, 1224-1231.
27. 27. Berners-Price S. J. and Sadler P. J. (1988) Phosphines and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity. Struct. Bonding 70, 27-102.
28. 28. Bingham M. J. and McArdle H. J. (1994) A comparison of copper uptake by liver plasma membrane vesicles and uptake by isolated cultured rat hepatocytes. Hepatology 20, 1024-1031.
29. 29. Bischof Delaloye A., Buchegger F., Smith A., Schubiger P. A., Maecke H. R., Poncioni L., Gillet M., Mach J. P. and Delaloye B. (1994) Cu-67-Anti-CEA MAB, a potential therapeutic agent: Biokinetic studies in patients with colon carcinoma. J. Nucl. Med. 35, 101P.
30. 30. Blower P. J. and Dilworth J. R. ( 1987) Thiolato-complexes of the transition metals. Coord. Chem. Rev. 76, 121-185.
31. 62Cu-PTSM. Appl. Radiat. Isot. 12, 1437-1441.
32. 32. Brown L. C. and Callahan A. P. (1972) The separation and purification of carrier-free copper isotopes for medical use. Appl. Radiat. Isot. 23, 535-538.
33. 33. Campbell C. H., Brown R. and Linder M. C. (1981) Circulating ceruloplasmin is an important source of copper for normal and malignant animal cells. Biochim. Biophys. Acta 678, 27-38.
34. 34. Chan-Stier C. H., Minkel D. and Petering D. H. (1976) Reactions of bis(thiosemicarbazonato) copper(II) complexes with tumor cells and mitochondria. Bioinorg. Chem. 6, 203-217.
35. 35. Chervu L. R. and Sternlieb I. (1974) Dosimetry of copper radionuclides. J. Nucl. Med. 15, 1011-1013.
36. 36. Chinol M., Mausner L. F., Mease R. C., Meinken G. E., Villela M. A., Steplewski Z. and Srivastava S. C. (1992) Evaluation of Cu-67 and Sm-153 immunoconjugates for tumor therapy. J. Nucl. Med. 33, 942P.
37. 210Pb in the rat. Br. J. Ind. Med. 29, 74-80.
38. 2O. J. Chem. Soc. Chem. Commun. 1244-1245.
39. 39. Clelland C. C., Giles K. D., Farley T. D., Gee Q. and Wright J. R. (1986) The intravenous distribution of a radiolabeled, potentially useful cluster ion of copper and penicillamine. Physiol. Chem. Phys. Med. NMR. 18, 37-40.
40. 40. Cole D. A., Mercer-Smith J. A., Schreyer S. A., Norman J. K. and Lavallee D. K. (1990) The biological characteristics of a water-soluble porphyrin in rat lymph nodes. Nucl. Med. Biol. 17, 457-464.
41. 41. Cole D. A., Moody D. C., Ellinwood L. E. and Klein M. G. (1991) Using 5,10,15,20-tetrakis(r-carboxyphenyl)prophine for detecting and treating lung cancer. International Patent WO 91/19977.
42. 42. Cole D. A., Moody D. C., Ellinwood L. E. and Klein M. G. (1991) 5,10,15,20-tetrakis(r-carboxyphenyl)porphine for detecting and treating lung cancer. International Patent WO 91/19978.
43. 57Co. Nucl. Med. Biol. 13, 363-368.
44. 44. Cole W. C., DeNardo S. J., Measures C. F., McCall M. J., DeNardo G. L., Epstein A. L., O'Brien H. A. and Moi M. K. (1987) Comparitive stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med. 28, 83-90.
45. 45. Connett J. M., Anderson C. J., Baumann M. L., Schwarz S. W., Zinn K. R., Philpott G. W. and Welch M. J. (1993) Cu-67 and Cu-64 labeled monoclonal antibody (Mab) 1A3 as potential agents for radioimmunotherapy. J. Nucl. Med. 34, 216P.
46. 64Cu de la croissance de la tumeur ascitique de Krebs chez la souris. Bull. Cancer (Paris) 69, 121-130.
47. 47. Cotton F. A. and Wilkinson G. (1988) Advanced Inorganic Chemistry, 5th edn. Wiley-Interscience, New York.
48. 48. Cutler P. D., Schwarz S. W., Eichung J. O., Philpott G. W. and Welch M. J. (1994) Whole-body dosimetry from PET images of monoclonal antibodies labeled with Cu-64. J. Nucl. Med. 35, 158P.
49. 49. Cutler P. D., Schwan S. W., Anderson C. J., Connett J. M., Welch M. J., Philpott C. W. and Siegel B. A. (1995) Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J. Nucl. Med. 36, 2363-2371.
50. 50. De Nardo G. L., DeNardo S. J., Meares C. F., Kukis D., Diril H., McCall M. J., Adams G. P., Mausner L. F., Moody D. C. and Deshpande S. V. (1991) Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibody Immunoconjug. Radiopharm. 4, 777-785.
51. 51. De Nardo G. L., Mirick G. R., Kroger L. A., De Nardo S. J., O'Donnell R. T. and Meares C. F. (1995) Human IgG responses to macrocyclic chelating agents (DOTA and TETA) in patients with B-lymphocytic malignancies. J. Nucl. Med. 36, 92P.
52. 52. Deshpande S. V., DeNardo S. J., Meares C. F., McCall M. J., Adams G. P., Moi M. K. and DeNardo G. L. (1988) Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: Labeling and biodistribution in RAJI tumored mice. J. Nucl. Med. 29, 217-225.
53. 64Cu using a conjugate containing a macrocylic amine chelating agent. Nucl. Med. Biol. 14, 479-484.
54. 54. Freedman J. H. and Peisach J. (1989) Intracellular copper transport in cultured hepatoma cells. Biodiem. Biophys. Res. Commun. 164, 134-140.
55. 55. Fritzberg A. R., Beringer R. W., Hadley S. W. and Wester D. W. (1988) Approaches to radiolabelling of antibodies for diagnosis and therapy of cancer. Pharm. Res. 5, 325-334.
56. 56. Fujibayashi Y., Matsumoto K., Yonekura Y., Konishi J. and Yokoyama A. ( 1989) A new zinc-62/copper-62 generator as a copper-62 source for PET Radiopharmaceuticals. J. Nucl. Med. 30, 1838-1842.
57. 62Cu generator system. Chem. Pharm. Bull. 38, 1946-1948.
58. 58. Fujibayashi Y., Wada K., Matsumoto K., Yonekura Y., Konishi J. and Yokoyama A (1991) Retention mechanism of Cu-62-PTSM, a generator-produced positron emitting Cu-62 labeled blood flow tracer. J. Nucl. Med. 32, 974.
59. 62-PTSM) in the murine brain: A novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol. Pharm. Bull. 16, 146-149.
60. 60. Fujibayashi Y., Taniuchi H., Tajima N., Yonekura Y., Konishi J. and Yokoyama A. ( 1995) New non-nitroimidazole hypoxia imaging agents, Cu-62-dithiosemicarbazone complexes with low redox potential. J. Nucl. Med. 36, 49P.
61. 4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: A novel radiopharmaceutical for positron emission tomography imaging. Ann. Nucl. Med. 9, 1-5.
62. 64Cu-labelled diethyl-HIDA. Appl. Radiat. Isot. 41, 237-238.
63. 4-methylthiosemicarbazone). Nucl. Med. Biol. 14, 59-61.
64. 64. Green M. A., Klippenstein D. L. and Tennison J. R. (1988) Coppert (II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J. Nucl. Med. 29, 1549-1557.
65. 4-methylthiosemibarbazonato)copper(II): Synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J. Nucl. Med. 31, 1989-1996.
66. 66. Green M. A., Welch M. J., Mathias C. J., Bergmann S. R., Perlmutter J. S., Raichle M. E., Rubio F. F. and Janik M. (1990) Copper-62-PTSM: Production and evaluation of a generator produced multipurpose PET perfusion agent. J. Nucl. Med. 31, 815P.
67. 67. Griffiths G. L., Goldenberg D. M., Diril H. and Hansen H. J. (1994) Technetium-99m, rhenium-186, and rhenium-188 direct-labelled antibodies. Cancer 73 (Suppl), 761-768.
68. 68. Gunther K., Lossner V., Lossner J. and Biesold D. (1975) The kinetics of copper uptake by the liver in Wilson's disease studies by a whole-body counter and a double labelling technique Eur. Neurol. 13, 385-394.
69. 69. Hnatowich D. J., Layne W. W., Childs R. L., Lanteigne D., Davis M. A., Griffin T. W. and Doherty P. W. (1983) Radioactive labeling of antibody: A simple and efficient method. Science 220, 613-614.
70. 70. Herrero P., Markham C., Weinheimer J., Green M. A., Welch M. J. and Bergmann S. R. (1991) Quantification of myocardial perfusion with Cu-62-PTSM and positron emission tomography. J. Nucl. Med. 32, 937P.
71. 62Cu-PTSM and positron emission tomography. Circulation 87, 173-183.
72. 72. Hesslewood I. P., Cramp W. A., McBrien D. C. H., Williamson P. and Lott K. A. K. (1978) Copper as a hypoxia cell sensitizer of mammalian cells. Br. J. Cancer 37 (Suppl III), 95-97.
73. 73. Hetherington E. L., Sorby P. J. and Camakaris J. (1986) The preparation of high specific activity copper-64 for medical diagnosis. Appl. Radiat. Isot. 37, 1242-1243.
74. 3He bombardments on cobalt target. Chem. Lett. 397-400.
75. 75. Iqbal S., Naqvi A. and Rizvi M. H. (1992) Replacement of native copper in superoxide dismutase with copper-64 without much loss in its enzymic activity. J. Radioanal. Nucl. Chem. 159, 9-12.
76. 4-methylthiosemicarbazone). Nucl. Med. Biol. 16, 791-797.
77. 77. John E. K. and Green M. A. (1990) Structure-activity relationships for metal-labeled blood flow tracers: Comparison of ketoaldehyde bis-(thiosemicarbazonato)copper(II) derivatives. J. Med. Chem. 33, 1764-1770.
78. 78. John E. K., Bott A. J. and Green M. A. (1994) Preparation and biodistribution of copper-67 complexes with tetradentate Schiff-base ligands. J. Pharm. Sci. 83, 587-590.
79. 79. Jones C. J. and McCleverty J. A. (1970) Complexes of transition metals with Schiff bases and the factors influencing their redox properties: Part I. Nickel and copper complexes of some diketone bis-thiosemicarbazones. J. Chem. Soc. A, 2829-2836.
80. 2- anion in the solid state: Molecular structure and disorder of sodium tricyanocuprate(I) trihydrate. Inorg. Chem. 17, 1945-1949.
81. 81. Karlin K. P. and Zubieta J. (1983) Copper Coordination Chemistry: Biochemical and Inorganic Perspectives. Adenine Press, New York.
82. 64Cu-bleomycin in Ehrlich ascites tumour cells in vitro. Annu. Rep. Res. Reactor Inst. Kyoto Univ. 12, 143-145.
83. 83. Kimura E., Koike T. and Takahashi M. (1985) Novel synthesis and complex properties of macrocyclic tetra-amines appended with phenol as an axial donor. J. Chem. Soc. Chem. Commun. 385-386.
84. 84. Kodama M. and Kimura E. (1976) Thermodynamic and kinetic effects of 12-membered macrocycles: Polarogaphic studies of 1,4,7,10-tetraazacyclododecancopper(II). J. Chem. Soc. Soc. Dalton Trans. 116-120.
85. 85. Kolsky K. L., Joshi V., Meinken G. E., Sweet M., Mausner L. F. and Srivastava S. C. (1992) Improved production, and evaluation of Cu-67 for tumor radioimmunotherapy. J. Nucl. Med. 35, 259P.
86. 86. Kraker A., Krezoski S., Schneider J., Minkel D. and Petering D. H. (1985) Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato)copper(II) with Erhlich cells. J. Biol. Chem. 260, 13710-13718.
87. 4 and [LCuI] (L = 1,4,7-trithiacyclononane). Angew. Chem. Int. Ed. Engl. 26, 575-576.
88. 88. Kukis D. L., Diril H., Greiner D. P., DeNardo S. J., DeNardo G. L., Salako Q. A. and Meares C. F. (1994) A comparative study of copper-67 radiolabelling and kinetic stabilies of antibody-macrocycle chelate conjugates. Cancer (Suppl) 73, 779-786.
89. 89. Kukis D. L., DeNardo G. L., DeNardo S. J., Mirick G. R., Miers L. A., Greiner D. P. and Meares C. F. (1995) Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 21T-BAT-Lym-1 immunoconjugates. Cancer Res. 55, 878-884.
90. 90. Lacy J. L., Chien S. C., Kim J. K., Mathias C. J. and Green M. A. (1995) Modular automated Zn-62/Cu-62 PET radiopharmaceutical generator. J. Nucl. Med. 36, 49P.
91. 91. Lan W.-J. and Chung C.-S. (1994) Kinetics of acid catalysed dissociation of tetraaza-macrocyclic ligand complexes of copper(II). J. Chem. Soc. Dalton Trans. 191-194.
92. 92. Lau S.-J. and Sarkar B. ( 1971 ) Ternary coordination complex between human serum albumin, copper(II), and L-histidine. J. Biol. Chem. 246, 5938-5943.
93. 93. Lee K. S., Mangner T. J., Petry N. A., Moskwa J. J. and Mintum M. A. (1991) Evaluation of Cu-62 PTSM in the detection of neural activation foci. J. Nucl. Med. 32, 1072P.
94. 94. Leonovikova T., Angelis B., Cifka J. and Cifkova I. (1984) Biological behaviour of some gallium-67 and copper-64 chelates. Radioisotopy 25, 685-698.
95. 95. Levason W. and Spicer M. D. (1987) The chemistry of copper and silver in their higher oxidation states. Coord. Chem. Rev. 76, 45-120.
96. 96. Lewis J. S., Zweit J., Carnochan P. and Blower P. J. (1995) Copper(I) bis(diphosphine) complexes as a basis for PET and therapeutic radiopharmaceuticals. J. Label. Compd. Radiopharm. 37, 465-467.
97. 97. Lewis J. S., Zweit J., Dearling J. L. J., Rooney B.C. and Blower P. J. (1996) Copper(I) bis(diphosphine) complexes as a basis for radiopharmaceuticals for positron emission tomography and targeted radiotherapy. Chem. Commun. 1093-1094.
98. 98. Lewis M. R., Raubitschek A. and Shively J. (1994) A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug. Chem. 5, 565-576.
99. 99. Linder M. C. (1991) Biochemistry of Copper. Plenum Press, New York.
100. 64Cu-bleomycin on Ehrlich ascites tumour cells in vivo. Annu. Rep. Res. Reactor Inst. Kyoto Univ. 12, 45-50.
101. 101. Martell A. E. and Smith R. M. 1974) Critical Stability Constants, Vol. 1, pp 204-285. Plenum Press, New York.
102. 102. Martin C. C., Oakes T. R. and Nickles R. J. (1990) Small cyclotron production of [Cu-60]Cu-PTSM for PET blood flow measurements. J. Nucl. Med. 31, 815P.
103. 103. Mather S. J. and Ellison D. (1990) Reduction-mediated technetium-99m labeling of monoclonal antibodies. J. Nucl. Med. 31, 692-697.
104. 104. Matthews S. E., Pouton C. W. and Threadgill M. D. (1995) Monofunctional electrophilic and nucleophilic derivatives of mesotetraphanylporphyrin for attachment to peptides. J. Chem. Soc. Chem. Commun. 1809-1811.
105. 105. Mathias C. J., Welch M. J., Green M. A., Perry D. J., McGuire A. H., Zhu X. and Connett J. M. (1990) Copper-PTSM measures tumor blood flow too! J. Nucl. Med. 31, 909-910P.
106. 106. Mathias C. J., Welch M. J., Green M. A., Diril H., Meares C. F., Gropler R. J. and Bergmann S. R. (1991) In vivo comparison of copper blood pool agents: Potential radiopharmaceuticals for use with copper-62. J. Nucl. Med. 32, 475-480.
107. 107. Mathias C. J., Welch M. J., Raichle M. E., Mintun M. A., Lich L. L., McGuire A. H., Zinn K. R., John E. K. and Green M. A. (1990) Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: Single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM. J. Nucl. Med. 31, 351-359.
108. 108. Mathias C. J., Bergmann S. R. and Green M. A. (1992) Development and validation of a solvent extraction technique for determination of Cu-PTSM in blood. Nucl. Med. Biol. 20, 343-349.
109. 109. Mathias C. J., Bergmann S. R. and Green M. A. (1995) Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin. J. Nucl. Med. 36, 1451-1455.
110. 62Cu generator. Radioisotopes 39, 486 (Abstract).
111. 62Cu-labeled bifunctional radiopharmaceuticals with metabolizable ester groups. Nucl. Med. Biol. 19, 33-38.
112. 62Cu-PTSM. Nucl. Med. Biol. 19, 39-44.
113. 113. Mausner L. F., Straub R. F. and Srivastava S. C. (1986) Production and use of prospective radionuclides for radioimmunotherapy. In: Radiolabelled Monoclonal Antibodies for Imaging and Therapy (Edited by Srivastava S. C.), pp. 149-163. Plenum Press, New York.
114. 64Cu]DTPA: New radiopharmaceuticals for quantitative tomocisternography. Appl. Radiat. Isot. 34, 595-598.
115. 115. McCall M. J., Diril H. and Meares C. F. (1990) Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug. Chem. 1, 222-226.
116. 116. McCarthy D., Shefer R., Klinkowstein R., Bass L., Margeneau W., Anderson C. and Welch M. (in press) The efficient production of high specific activity copper-64 using a biomedical cyclotron. J. Nucl. Med.
117. 117. McPherson D. W., Umbricht G. and Knapp F. F. Jr. (1990) Radiolabeling of proteins with radioisotopes of copper using p-carboxyalkylphenylglyoxal bis-(4N-methylthiosemicarbazone) (TSC) bifunctional chelates. J. Label. Compd. Radiopharm. 28, 877-899.
118. 118. Meares C. F. and Wensel T. G. (1984) Metal chelates as probes of biological systems. Acc. Chem. Res. 17, 202-209.
119. 119. Meares C. F. (1986) Attaching metal ions to antibodies. In: Protein Tailoring for Food and Medical Uses (Edited by Feeney R. E. and Whitaker S. R.), pp. 339-352. Marcel Dekker, New York.
120. 120. Mease R. C., Chinol M., Mausner L. F., Steplewski Z. and Srivastava S. C. (1992) New simple synthesis and activation of 1,4,7,10-tetraazacyclododecane-and 1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N‴-tetraacetic acid (DOTA and TETA) for immunoconjugation. J. Nucl. Med. 33, 942-943P.
121. 121. Meister A. and Anderson M. E. (1983) Glutathione. Annu. Rev. Biochem. 52, 711-760.
122. 122. Melon P. G., Brihaye C., Degueldre C., Guillaume M., Czichosz R., Rigo P., Kulbertus H. E. and Comar D. (1994) Myocardial kinetics of potassium-38 in humans and comparison with copper-62-PTSM. J. Nucl. Med. 35, 1116-1122.
123. 123. Mercer-Smith J. A., Roberts J. C., Figard S. D. and Lavellee D. K. (1988) The development of copper-67-labeled porphyrin-antibody conjugates. In: Targeted Diagnosis and Therapy: Vol. 1. Antibody-Mediated Delivery Systems, pp. 317-352. Marcel Dekker, New York.
124. 124. Minkel D. T. and Petering D. H. (1978) Initial reaction of 3-ethoxy-2-butyraldehyde bis-thiosemicarbazonato) copper(II) with Erhlich ascites tumour cells. Cancer Res. 38, 117-123.
125. 125. Mirzadeh S., Mausner L. F. and Srivastava S. C. (1986) Production of no-carrier added 67Cu. Appl. Radiat. Isot. 37, 29-36.
126. 126. Mirzadeh S. and Knapp F. F. Jr. (1992) Spontaneous electrochemical separation of carrier-free copper-64 and copper-67 from zinc targets. Radiochim. Acta. 57, 193-199.
127. 127. Moi M. K., Meares C. F., McCall M. J., Cole W. C. and DeNardo S. J. (1985) Copper chelates as probes of biological systems: Complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem. 148, 249-243.
128. 128. Moi M. K., Yanuck M., Deshpande S. V., Hope H., DeNardo S. J. and Meares C. F. (1987) X-ray crystal structure of a macrocyclic copper chelate stable enough for use in living systems: Copper(II) dihydrogen 6-(p-nitrobenzyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetate. Inorg. Chem. 26, 3458-3463.
129. 129. Moi M. K., DeNardo S. J. and Meares C. F. (1990) Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. (Suppl) 50, 789-793.
130. 130. Morphy J. R., Parker D., Kataky R., Harrison A., Eaton M. A. W., Millican A., Phipps A. and Walker C. (1989) Towards tumour targeting with copper-radiolabelled macrocycle-antibody conjugates. J. Chem. Soc. Chem. Commun. 792-794.
131. 131. Munaka M. and Endicott J. F. (1984) Oxidation-reduction reactions of complexes with macrocyclic ligands: Role of kinetic factors in distinguishing mechanistic pathways in reactions of copper(I) complexes with coordinated dinitrogen. Inorg. Chem. 23, 3693-3698.
132. 132. Muramatsu H., Shirai E., Nakahara H. and Murakami Y. (1978) Alpha particle bombardment of natural nickel target for the production of Cu-61. Appl. Radiat. Isot. 29, 611-615.
133. 64Cu. Appl. Radiat. Isot. 28, 802-804.
134. 2- anion: X-ray crystal and molecular structure of bis(1-methyl-4-oxo-3,3-diphenyl-hexyldimethylammonium)tetrachlorocuprate(II). J. Chem. Soc. Chem. Commun. 632-633.
135. 135. Novak-Hofer I., Amstutz H. P., Maecke H. R., Schwarzbach R., Zimmermann K., Morgenthaler J-J. and Schubiger P. A. (1995) Cellular processing of copper-67-labeled monoclonal antibody ChCE7 by human neuroblastoma cells. Cancer Res. 55, 46-50.
136. 136. O'Brien H. A., Barnes J. W., Taylor W. A., Thomas K. E. and Bentley G. E. (1984) Copper-67 production. United States Patent 4,487,738.
137. 137. O'Brien H. A., Jr (1969) The preparation of Cu-67 from Zn-67 in a nuclear reactor. Appl. Radiat. Isot. 20, 121-124.
138. 138. O'Donoghue J. A., Bardies M. and Wheldon T. E. (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36, 1902-1909.
139. 139. O'Hara J. A., Douple E. B., Abrams M. J., Giandomenico G. M., Bradley F. C., McElligott M. A. and Caruso F. S. (1992) Combined modality treatment with ternary Cu(II) complexes and X-Rays. Int. J. Radiation Oncology Biol. Phys. 22, 607-612.
140. 140. Okazawa H., Yonekura Y., Fujibayashi Y., Nishizawa S., Magata Y., Ishizu K., Tanaka F., Tsuchida T., Tamaki N. and Konishi J. (1994) Clinical application and quantitative evaluation of generator-produced copper-62-PTSM as a brain perfusion tracer for PET. J. Nucl. Med. 35, 1910-1915.
141. 67Cu): Abnormal scintiscans in patients with Wilson's disease. Q. J. Med. 38, 467-474.
142. 142. Owen C. A. (1982). Wilson's disease: The etiology. In: Clinical Aspects and Treatment of Inherited Copper Toxicosis. Noyes Publications, Park Ridge, New Jersey.
143. 143. Owens G. D., Phillips D. A., Czarnecki J. J., Raycheba J. M. T. and Margerum D. W. (1984) Electron-transfer kinetics of the reactions between copper(III,II) and nickel(III,II) deprotonated-peptide complexes. Inorg. Chem. 23, 1345-1353.
144. 144. Pal I., Foldes J. and Krasznai I. (1973) Pharmacological control of radioactive metal complexes. Isotoptechnika 16, 418-422.
145. 145. Parker D., Morphy J. R., Jankowski K. and Cox J. (1989) Implementation of macrocycle conjugated antibodies for tumour-targetting. Pure Appl. Chem. 61, 1637-1641.
146. 146. Parker D. (1990) Tumour targeting with radiolabelled macrocycle-antibody conjugates. Chem. Soc. Rev. 19, 271-291.
147. 147. Pastakia B., Liberman L. M., Gatley S. J., Young D., Petering D. H. and Minkel D. (1980) Tissue distribution of copper-labeled 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone) (Cu-64 KTS) in mice and rats: Concise communication. J. Nucl. Med. 21, 67-70.
148. 148. Pearson R. G. (1963) Hard and soft acids and bases. J. Am. Chem. Soc. 85, 3533-3539.
149. 149. Petering D. H. (1972) Physicochemical properties of the anti-tumor agent 3-ethoxo-2-oxobutyraldehyde bis-(thiosemicarbazonato)-copper(II). Bioinorg. Chem. 1, 255-271.
150. 150. Petering D. H. (1972) The reaction of 3-ethoxo-2-oxobutyraldehyde bis(thiosemicarbazonato)copper(II) with thiols. Bioinorg. Chem. 1, 273-288.
151. 151. Petering D. H. (1980) Carcinostatic copper complexes. In: Metal Ions in Biological Systems (Edited by Sigel H.), pp. 197-229. Marcel Dekker, New York.
152. 152. Petering H. G., Buskirk H. H. and Underwood G. E. (1964) Antitumor action of 2-oxo-3-ethoxybutyraldehyde bis(thiosemicarbazone) and similar compounds. Cancer Res., 24, 367-372.
153. 153. Pettit L. D., Steel I., Kowalik T., Kozlowski H. and Bataille M. (1985) Specific binding of the tyrosine residue in copper(II) complexes of Try-Pro-Gly-Tyr and Tyr-Gly-Pro-Tyr. J. Chem. Soc. Dalton Trans. 1201-1205.
154. 154. Pettit L. D., Steel I., Formicka-Koslowska G., Tatarowski T. and Bataille M. (1985) The L-proline residue as a "break-point" in metal-peptide systems. J. Chem. Soc. Dalton Trans. 535-539.
155. 155. Philpott G. W., Schwarz S. W., Anderson C. J., Griffeth L. K., Connett J. M., Zinn K. R., Meares C. F., Siegel B. A. and Welch M. J. (1993) Initial clinical study of Cu-64-labeled anticolon carcinoma monoclonal antibody (MAB 1A3) in colorectal cancer. J. Nucl. Med. 34, 81P.
156. 2] in patients with colorectal cancers. J. Nucl. Med. 36, 9P.
157. 157. Philpott G. W., Schwarz S. W., Anderson C. J., Dehdashti F., Connett J. M., Zinn K. R., Meares C. F., Cutler P. D., Welch M. J. and Siegel B. A. (1995) RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med. 36, 1818-1824.
158. 62Cu at a small cyclotron. Radiochim. Acta. 57, 1-5.
159. 67Cu: Preliminary results. J. Nucl. Med. 14, 947-950.
160. 160. Renault H., Rapin J. and Wicart L. (1971) La chélation de divers cations radioactifs par certain polypeptides, utilisée comme méthode de marquage. application à la bléomycine. C. R. Acad. Sci. Paris 273, 2013-2015.
161. 161. Renault H., Henry R., Rapin J. and Hegesippe M. (1973) Chelation of radioactive cations by a polypeptide, bleomycin. Proc. Symp. New Develop. Radiopharm. Label Comp. 2, 195-202.
162. 162. Roberts J. C., Figard S. D., Mercer-Smith J. A., Svitra Z. V., Anderson W. L. and Lavallee D. K. (1987) Preparation and characterization of copper-67 porphyrin-antibody conjugates. J. Immunol. Methods 105, 153-164.
163. 163. Roberts J. C., Newmyer S. L., Mercer-Smith J. A., Schreyer S. A. and Lavallee D. K. (1989) Labelling antibodies with copper radionuclides using N-4-nitrobenzyl-5-(4-carboxyphenyl)-10,15,20-tris(4-sulfophenyl) prophine. Appl. Radiat. Isot. 40, 775-781.
164. 164. Robinson G. D. and Lee A. W. (1977) Copper-62 radiopharmaceuticals. J. Label. Compd. Radiopharm. 13, 187.
165. 165. Robinson G. D., Zielinski F. W. and Lee A. W. (1980) The zinc-62/ copper-62 generator: A convenient source of copper-62 for radiopharmaceuticals. Appl. Radiat. Isot. 31, 111-116.
166. 64Cu-bleomycin. J. Nucl. Med. 16, 127-131.
167. 167. Saji H., Saiga A., Ieda Y., Magata Y. and Yokoyama A. (1992) Synthesis and in vivo behavior of a copper-64-labeled dithiosemicarbazone derivative coupled to a dihydropyridine carrier. J. Label. Compd. Radiopharm. 33, 127-135.
168. 51Cr in man. Int. J. Nucl. Med. Biol. 6, 17-21.
169. 169. Schwarz S. W., Cutler P. D., Eichung J. I., Anderson C. J., Connett J. M., Guo L. W., Philpott G. W., Siegel B. A, and Welch M. J. ( 1995) Tumor dosimetry for Cu-64 and Cu-67-labeled Mab 1A3 for radioimmunotherapy. J. Nucl. Med. 36, 181P.
170. 67Cu from irradiated zinc for use in antibody labelling: A comparison of methods. Appl. Radiat. Isot. 46, 329-336.
171. 171. Shelton M. E., Green M. A., Mathias C. J., Welch M. J. and Bergmann S. R. (1989) Kinetics of copper-PTSM in isolated hearts: A novel tracer for measuring blood flow with positron emission tomography. J. Nucl. Med. 30, 1843-1847.
172. 172. Shelton M. E., Green M. A., Mathias C. J., Welch M. J., and Bergmann S. R. (1990) Assessment of regional myocardial and renal blood flow using copper-PTSM and positron emission tomography. Circulation 82, 990-997.
173. 173. Shen S., DeNardo G. L., DeNardo S. J., Salako Q., Morris G., Banks D., Yuan A. and DeNardo D. A. (1996) Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. J. Nucl. Med. 37, 146-150.
174. 174. Sieving P. F., Watson A. and Rocklage S. M. (1990) Chelants. Int. Pat. Appl. PCT/EP90/00565.
175. 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res. 53, 5727-5733.
176. 131l-labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small-cell lung cancer. Int. J. Cancer (Suppl) 8, 43-48.
177. 177. Smith A. (1995) Personal communication.
178. 178. Smith-Jones P., Fridrich R., Kaden T. A., Novak-Hofer I., Siebold K., Tschudin D. and Maecke H. R. (1991) Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid. Bioconjug. Chem. 2, 415-421.
179. 179. Sorenson J. R. J. (1982) The anti-inflammatory activities of copper complexes. In: Metal Ions in Biological Systems (Edited by Siegel H.), Vol. 14. Marcel Dekker, New York, pp. 77-92.
180. 180. Stetter H., Frank W. and Mertens R. (1981) Darstellung und komplexbildung von polyazacycloalkan-n-essigsauren. Tetrahedron 37, 767-772.
181. 181. Stone C. K., Martin C. C., Mueller B., Pyzalski R. A., Perlman S. B. and Nickles R. J. (1991) Comparison of myocardial uptake of copper pyruvaldehyde thiosemicarbazone with N-13 ammonia in humans by PET. J. Nucl. Med. 32, 999P.
182. 182. Stone C. K., Christian B. T., Nickles R. J., Carlson K. J. and Perlman S. B. (1994) Quantitation of myocardial perfusion with Cu-62-PTSM PET: Impact of input function correction. J. Nucl. Med. 35, 78P.
183. 2+. Helv. Chim. Acta. 69, 2081-2086.
184. 184. Subczynski W. K., Antholine W. E., Hyde J. S. and Petering D. H. (1987) Orientation and mobility of a square-planar complex in a lipid bilayer. J. Am. Chem. Soc. 109, 46-52.
185. 185. Szelecsenyi F., Blessing G. and Qaim S (1993) Excitation functions of proton induced nuclear reactions on enriched Ni-61 and Ni-64: Possibility of production of no-carrier-added Cu-61 and Cu-64 in a small cyclotron. Appl. Radiat. Isot. 44, 575-580.
186. 186. Tadamura E., Tamaki N., Kawamoto K., Okazawa H., Fujibayashi Y., Magata Y., Yonekura Y., Torizuka T., Nohara R., Sasayama S. and Konishi J. (1994) Value and limitation of copper-62 pyruvaldehyde bis-methylthiosemicarbazone as a myocardial perfusion tracer for PET. J. Nucl. Med. 35, 156P.
187. 187. Tanaka S. (1960) Reactions of nickel with alpha particles. J. Phys. Soc. Jap. 15, 2159-2167.
188. 4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: A potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET). Biol. Pharm. Bull. 18, 1126-1129.
189. 2. J. Cryst. Mol. Struct. 5, 329-341.
190. 190. Teo B.-K. and Barnes D. M. (1976) Application of far infrared spectroscopy to structural determination of (pnicogen ligand)-(coinage metal)-halogen cluster systems. Inorg. Nucl. Chem. Lett. 12, 681-687.
191. 64Cu-bleomycin in normal and tumour bearing rats. Eur. J. Cancer 12, 19-23.
192. 192. Ueda N., Nakamoto S., Tanaka Y., Hazue M., Fujibayashi Y. and Yokoyama A. (1983) Production of Zn-62 and development of Zn-62/ Cu-62 generator system. J. Nucl. Med. 24, 124P.
193. 193. Van Giessen G. J. and Petering H. G. (1968) Metal complexes of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone) and related ligands as antitumor agents. J. Med. Chem. 11, 695-699.
194. 4-methylthiosemicarbazone)], a stable superoxide dismutase-like copper complex with high membrane penetrability. Arch. Biochem. Biophys. 310, 1-5.
195. 67Cu. J. Clin. Invest. 46, 10-20.
196. 64Cu) in Wilson's disease and various control groups. Q. J. Med. 46, 445-462.
197. 46Ar(d,a). Phys. Rev. 130, 265-267.
198. 67Cu) and the diagnosis of Wilson's disease. Mayo Clin. Proc. 49, 387-393.
199. 199. Wu R. S. (1989) Preparation of radiolabeled conjugates. European Patent Appl. 306, 168.
200. 68Zn(g,p) reaction. Appl. Radiat. Isot. 29, 756-75.
201. 62Cu generator. Int. J. Appl. Radiat. Isot. 30, 569-570.
202. 4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur. J. Nucl. Med. 21, 336-341.
203. 203. Zamora P. O., Mercer-Smith J. A., Marek M. J., Schulte L. D. and Rhodes B. A. (1992) Similarity of copper and technetium binding sites in human IgG. Nucl. Med. Biol. 19, 797-802.
204. 204. Zinn K., Chaudhuri T., Cheng T.-P., Morris J. and Meyer W. (1994) Production of no-carrier-added Cu-64 from zinc metal irradiated with under boron sheilding. Cancer (Suppl) 73, 774-778.
205. 205. Zuckman S. A., Freeman G. W., Troutner D. E., Volkert W. A., Holmes R. A., VanDerveer D. G. and Barefield E. K. (1981) Preparation and X-ray structure of trans-dioxo(1,4,8,11-tetrazacyclotetradecane)technetium(v) perchlorate hydrate. Inorg. Chem. 20, 2386-2389.
206. 64Ni targets for positron emission tomography. Appl. Radiat. Isot. 42, 193-197.
207. 207. Zweit J., Goodall R., Cox M., Babich J. W., Potter G. A., Sharma H. L. and Ott R. J. (1992) Development of a high-performance zinc-62/ copper-62 radionuclide generator for positron emission tomography. Eur. J. Nucl. Med. 19, 418-425.
208. 208. Zweit J., Flower M., Burke D., Davies M., Hall A., Mundy J., Young H., Carnochan P., Allen-Mersh T. and Ott R. (in press) Clinical pet using a remote cyclotron: Use of copper-62-PTSM in patients with colorectal liver metastases. J. Nucl. Med.
209. 209. Zweit J. (in press) Medium half-life inorganic radionuclides for PET Imaging. In: Current Directions in Radiopharmaceutical Research and Development (Edited by Mather S. J.) Kluwer Academic Publishers,
210. 210. Zweit J. (in Press) Radionuclides and carrier molecules for cancer therapy. Phys. Med. Biol.